Development of IL‐17A inhibitor‐induced atopic dermatitis‐like rash in psoriasis patients: Insights into immune shift

• DOI: 10.1111/exd.14958
• Publication Date: 2023-11-27T15:03:16Z
• Authors: Qiuju Li; Xiuying Li; Wenyu Li; Runge Fan; Qing Ma; Xiaomei Luo; Huahui Jian; Xiaozhi Chen; Cunwei Cao; Wenjun Zheng
• Keywords: Interleukin-23; Skin biopsy

Abstract Cases of atopic dermatitis (AD)‐like rash induced by IL‐17A inhibitor secukinumab treatment (SI‐AD) have been recently reported in psoriasis patients. To identify immune and inflammatory factors expression SI‐AD. A panel 15 peripheral blood samples from various groups, including patients with SI‐AD, (S‐stable), advanced (Advanced) healthy controls (HC). Interleukin‐10 (IL‐10), IL‐4 were detected skin tissue biopsy immunohistochemistry real‐time quantitative polymerase chain reaction. The immunoglobulin E levels the SI‐AD exceeded normal values. IL‐10 higher than those S‐stable patients, HC. that HC, but no significant differences observed between AD‐like rashes skin, while did not differ significantly two. Upon discontinuing secukinumab, switching to oral cyclosporine, antihistamines, Janus kinase 1 topical glucocorticoids, experienced improvement their lesions. reexamination, all returned levels. Immune shift Th17 towards Th2 may occur as indicated abnormal multiple tissues.